ライフサイエンスコーパス: prasugrel

1 n but not greater IPA compared with integral prasugrel.

2 yocardial infarction, 26.0% of whom received prasugrel.

3 risk reduction appeared to be enhanced with prasugrel.

4 ged ACS patients treated with clopidogrel or prasugrel.

5 e investigated the PK/PD effects of crushing prasugrel.

6 absorption with crushed compared with whole prasugrel.

7 who were randomized to either clopidogrel or prasugrel.

8 t reactivity rates were reduced with crushed prasugrel.

9 ation drug-eluting stents and 19.5% received prasugrel.

10 ose aspirin, and 2 patients were also taking prasugrel.

11 ated with aspirin and risk-adjusted doses of prasugrel.

12 7; P=0.007) were both reduced with prolonged prasugrel.

13 cts of switching patients from ticagrelor to prasugrel.

14 t of aspirin dose on the clinical effects of prasugrel.

15 ved placebo received a 60-mg loading dose of prasugrel.

16 with either 100 mg (n=47) or 60 mg (n=35) of prasugrel.

17 opidogrel or replacement of clopidogrel with prasugrel.

18 the dose of clopidogrel or were switched to prasugrel.

19 assigned to ticagrelor and 1,186 assigned to prasugrel.

20 syndrome, and in this group, 17.2% received prasugrel.

21 arged on ticagrelor while far fewer received prasugrel.

22 cantly in patients assigned to ticagrelor or prasugrel.

23 =0.010) was higher with ticagrelor than with prasugrel.

24 further randomized to receive ticagrelor or prasugrel.

25 uring maintenance therapy with ticagrelor or prasugrel.

26 was planned to receive either ticagrelor or prasugrel.

27 blind, placebo-controlled crossover trial of prasugrel.

28 absolute reduction in the ischemia risk with prasugrel=1.5+/-3.0%, ranging from an 8.4% increased ris

29 Rates of mild bleeding were higher with prasugrel 10 mg but similar for prasugrel 5 mg versus cl

30 e primary PD noninferiority criterion versus prasugrel 10 mg in NE.

31 ndomized to continue ticagrelor or switch to prasugrel 10-mg once-daily MD, with or without a 60-mg L

32 mitigate the bleeding risk of standard-dose prasugrel (10 mg/d).

33 At hour 2, prasugrel 100 mg over 60 mg loading dose significantly r

34 relor versus prasugrel (ticagrelor, -13.9 U; prasugrel, -13.5 U; P=0.96).

35 likely to stop/switch therapy as compared to prasugrel (15.9% vs. 9.2%, p = 0.016).

36 cagrelor, 21 [interquartile range, 15-39] U; prasugrel, 18 [interquartile range, 11-29] U; P=0.08).

37 eated with clopidogrel (39.93), but not with prasugrel (3.87).

38 stenting to loading with clopidogrel 600 mg, prasugrel 30 mg, or prasugrel 60 mg.

39 rwent PCI; 1,394 received pre-treatment with prasugrel (30-mg loading dose), and 1,376 received place

40 elor was more effective than genotyping with prasugrel ($30 200 per QALY relative to clopidogrel).

41 different in patients on ticagrelor (28%) or prasugrel (41%; P=0.35).

42 Prasugrel 5 mg in VE met the primary PD noninferiority c

43 higher with prasugrel 10 mg but similar for prasugrel 5 mg versus clopidogrel 75 mg.

44 Low-dose prasugrel (5 mg/d) is recommended for younger, lower-bod

45 ignificantly lower with ticagrelor than with prasugrel (52 [32-72] versus 83 [63-103]; least-square m

46 ich did not provide higher IPA over integral prasugrel (6.3+/-11.4; P=0.47), despite yielding higher

47 l tested the hypothesis that in elective PCI prasugrel 60 mg (ILS) is superior to standard loading st

48 clopidogrel (600 mg, n=13 or 900 mg, n=12), prasugrel 60 mg (n=10), or ticagrelor 180 mg (n=10) were

49 acebo/prasugrel 60 mg and clopidogrel 600 mg/prasugrel 60 mg (primary outcome) was 22.2 (-11.0 to 55.

50 fidence interval) difference between placebo/prasugrel 60 mg and clopidogrel 600 mg/prasugrel 60 mg (

51 The pharmacodynamic response of prasugrel 60 mg ld alone was compared with prasugrel 60

52 At 6 hours after the prasugrel 60 mg LD, the least squares mean (95% confiden

53 f prasugrel 60 mg ld alone was compared with prasugrel 60 mg or 30 mg added 24 hours to clopidogrel 6

54 ding dose of intravenous LA 450 mg plus oral prasugrel 60 mg or loading dose of aspirin 300 mg plus p

55 60 mg or loading dose of aspirin 300 mg plus prasugrel 60 mg orally in a crossover fashion after a 2-

56 with clopidogrel 600 mg, prasugrel 30 mg, or prasugrel 60 mg.

57 rgoing PPCI (n = 52) who were treated with a prasugrel 60-mg loading dose (LD) either as whole or cru

58 ry disease were randomly assigned to receive prasugrel (60 mg loading dose [LD]/10 mg maintenance dos

59 patients treated initially in-hospital with prasugrel, 751 (11.5%) were discharged on clopidogrel.

60 elor, 7.6 [interquartile range, 3.7-14.4] g, prasugrel 9.9 [interquartile range, 5.7-16.6] g; P=0.17)

61 grastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in

62 6.3+/-11.4; P=0.47), despite yielding higher prasugrel active metabolite concentration (ng/mL; 62.3+/

63 ed odds ratio, 1.13 [95% CI, 1.09-1.18]) and prasugrel (adjusted odds ratio, 1.27 [95% CI, 1.21-1.34]

64 ate the effects of cangrelor, tirofiban, and prasugrel, administered as chewed or integral loading do

65 started immediately after randomization and prasugrel after coronary angiography.

66 l duration of dual antiplatelet therapy with prasugrel after TAXUS Liberte paclitaxel-eluting stent r

67 d persistence of the efficacy advantage with prasugrel after the first month.

68 Genotyping with prasugrel was superior to prasugrel alone, with an ICER of $35 800 per QALY relati

69 rred in 8.1% of patients assigned to receive prasugrel and 10.6% of those assigned to receive ticagre

70 red in 12.7% of patients assigned to receive prasugrel and 14.6% of those assigned to receive ticagre

71 for economic reasons was 34.1% (n = 216) for prasugrel and 44.4% (n = 265) for ticagrelor (p = 0.003)

72 rred in 4.8% of patients assigned to receive prasugrel and 7.3% of those assigned to receive ticagrel

73 ent oral aspirin challenges after 4 weeks of prasugrel and after 4 weeks of placebo.

74 Prasugrel and aspirin continued for 30 months reduced is

75 Treatment with prasugrel and aspirin improves outcomes compared with cl

76 obability of treatment weighting adjustment, prasugrel and clopidogrel had similar major adverse card

77 (A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Sub

78 (The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspiri

79 ncreased from 18.0% to 44.0%, while rates of prasugrel and clopidogrel use decreased from 24.6% to 13

80 ght to evaluate the impact of treatment with prasugrel and high-dose clopidogrel on the basis of plat

81 not show any significant difference between prasugrel and ticagrelor (2.7% and 2.5%, respectively; o

82 oint did not differ between groups receiving prasugrel and ticagrelor (4.0% and 4.1%, respectively; o

83 zation may improve the cost-effectiveness of prasugrel and ticagrelor after percutaneous coronary int

84 It has been documented that prasugrel and ticagrelor are able to provide effective p

85 s in acute coronary syndrome have shown that prasugrel and ticagrelor are more effective than standar

86 Prasugrel and ticagrelor are similarly effective during

87 ts defined by VerifyNow were similar between prasugrel and ticagrelor at 30 minutes and 2 hours post-

88 gometry, and Multiplate were similar between prasugrel and ticagrelor at each time point, including a

89 This head-to-head comparison of prasugrel and ticagrelor does not support the hypothesis

90 here were no significant differences between prasugrel and ticagrelor for all outcomes explored.

91 In patients with acute coronary syndromes, prasugrel and ticagrelor further reduce cardiovascular i

92 PRU <240 was 3 +/- 2 h and 5 +/- 4 h in the prasugrel and ticagrelor groups, respectively.

93 latelet reactivity rate between the combined prasugrel and ticagrelor groups.

94 signed to compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction

95 This study sought to compare the action of prasugrel and ticagrelor in ST-segment elevation myocard

96 of patients in the PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myoca

97 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myoca

98 t reactivity reduced significantly with both prasugrel and ticagrelor LD and maintenance dose.

99 ever, the pharmacodynamic measurements after prasugrel and ticagrelor LD have been provided by assess

100 e (P < 0.001) and without difference between prasugrel and ticagrelor patients.

101 Prasugrel and ticagrelor provide a superior anti-ischemi

102 Prasugrel and ticagrelor reduce thrombotic complications

103 Prasugrel and ticagrelor reduced ischemic events and inc

104 analyses of pivotal clinical trials testing prasugrel and ticagrelor versus clopidogrel showed DM pa

105 Differences between prasugrel and ticagrelor were not statistically signific

106 clude the next-generation antiplatelet drugs prasugrel and ticagrelor, and, in terms of anticoagulant

107 Prasugrel and ticagrelor, new P2Y12-adenosine diphosphat

108 Next-generation P2Y12 antagonists, prasugrel and ticagrelor, overcome these limitations and

109 ermined by VerifyNow P2Y12 at 1 week between prasugrel and ticagrelor.

110 as no efficacy and safety difference between prasugrel and ticagrelor.

111 difference in the primary end point between prasugrel and ticagrelor.

112 a comparison of efficacy and safety between prasugrel and ticagrelor; and 2) the risk of major ische

113 t with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned

114 th ticagrelor) or prasugrel (genotyping with prasugrel) and noncarriers receiving clopidogrel.

115 ticagrelor and 1.0% of patients assigned to prasugrel, and definite stent thrombosis occurred in 1.1

116 s-of-function alleles received ticagrelor or prasugrel, and noncarriers received clopidogrel.

117 tirofiban and cangrelor compared with chewed prasugrel, and superiority of chewed prasugrel as compar

118 asugrel received an additional 30-mg dose of prasugrel, and those who received placebo received a 60-

119 The P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are administered in fixed dos

120 for clopidogrel 600 mg, clopidogrel 900 mg, prasugrel, and ticagrelor, respectively; P for trend <0.

121 ns obtained thus far from subgroup analyses, prasugrel appears to provide higher anti-ischemic protec

122 Clopidogrel and prasugrel are not uncommonly switched in-hospital in pat

123 with clopidogrel, antiplatelet responses to prasugrel are not uniform.

124 yndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patient

125 Background Ticagrelor and prasugrel are potent P2Y12 inhibitors with superior effi

126 any reaction to aspirin challenge after the prasugrel arm.

127 chewed prasugrel, and superiority of chewed prasugrel as compared with integral prasugrel, each with

128 Data regarding prasugrel as part of triple therapy are not available.

129 ior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events

130 mized, double-blind ACCOAST (A Comparison of prasugrel at the time of percutaneous Coronary intervent

131 Bleeding outcomes tended to be higher with prasugrel but did not differ significantly between treat

132 MI rates increased within 90 days of prasugrel cessation after both 12 and 30 months treatmen

133 fidence interval </=45), although PRU in the prasugrel cohort was lower at 7 days than at 24 or 48 h.

134 hemic or bleeding outcomes with reduced-dose prasugrel compared with clopidogrel in elderly patients.

135 odynamic properties and clinical efficacy of prasugrel compared with clopidogrel, antiplatelet respon

136 ing occurred significantly more often in the prasugrel compared with the clopidogrel group (6 [28.6%)

137 -weight patients with ACS, a reduced dose of prasugrel compared with the standard dose of ticagrelor

138 TIMI 38, the safety and efficacy outcomes of prasugrel compared with those of clopidogrel were direct

139 reactions, P2Y(12) receptor antagonism with prasugrel completely inhibited all aspirin-induced react

140 (A Comparison of Prasugrel [CS-747] and Clopidogrel in Acute Coronary Syn

141 (Comparison of Prasugrel [CS-747] and Clopidogrel in Acute Coronary Syn

142 In the overall study population, prasugrel did not attenuate aspirin-induced symptoms, po

143 o undergo catheterization, pretreatment with prasugrel did not reduce the rate of major ischemic even

144 Prasugrel did not significantly change the mean increase

145 P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation.

146 f chewed prasugrel as compared with integral prasugrel, each with alpha=0.016 for the primary end poi

147 luding the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covale

148 ce, before transfer, a 60-mg loading dose of prasugrel either as crushed or integral tablets.

149 These findings suggest that substitution of prasugrel for clopidogrel in patients needing triple the

150 nosis; and antiplatelet agents vorapaxar and prasugrel for reducing cardiovascular events in patients

151 r ticagrelor (genotyping with ticagrelor) or prasugrel (genotyping with prasugrel) and noncarriers re

152 ticagrelor and in 73 (6.3%) patients in the prasugrel group (hazard ratio [HR]: 1.41; 95% confidence

153 agrelor group and in 4.8% of patients in the prasugrel group (hazard ratio, 1.12; 95% CI, 0.83 to 1.5

154 relor group and in 39 patients (5.1%) in the prasugrel group (hazard ratio, 1.22 [95% CI, 0.80-1.87];

155 relor group and in 64 patients (7.9%) in the prasugrel group (hazard ratio, 1.31 [95% CI, 0.95-1.82];

156 up and in 137 of 2006 patients (6.9%) in the prasugrel group (hazard ratio, 1.36; 95% confidence inte

157 ticagrelor and in 41 (4.7%) patients in the prasugrel group (HR: 1.09; 95% CI: 0.72 to 1.65).

158 risis events per person-year was 2.30 in the prasugrel group and 2.77 in the placebo group (rate rati

159 ry end point in the ticagrelor group and the prasugrel group were as follows: death, 4.5% and 3.7%; m

160 ity unit values and lower weight only in the prasugrel group, there was a nonsignificant treatment-by

161 emained significantly higher in the combined prasugrel groups versus the ticagrelor group (least-squa

162 eactivity were higher at 24 and 48 h in both prasugrel groups.

163 and bleeding outcomes (1.18; 0.77-1.80), but prasugrel had a lower rate of stent thrombosis (0.51; 0.

164 Regardless of low- or high-dose aspirin use, prasugrel had lower rates of the primary efficacy endpoi

165 < 0.0001), and patients who were switched to prasugrel had similar outcomes (HR: 0.90; 95% CI: 0.44 t

166 urs after the standard 60 mg loading dose of prasugrel has been described.

167 of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the hi

168 The oral P2Y12 antagonists ticagrelor and prasugrel have higher recommendations than clopidogrel,

169 tically significant mortality reduction with prasugrel (HR, 0.90 [95% CI, 0.80-1.01] and HR, 0.92 [95

170 In comparison with clopidogrel, both prasugrel (HR, 1.26 [95% CI, 1.01-1.56]) and ticagrelor

171 4.17; p = 0.04) than in patients switched to prasugrel (HR: 0.45; 95% CI: 0.11 to 1.91; p = 0.28).

172 of the primary endpoint whether treated with prasugrel (HR: 0.82) or clopidogrel (HR: 0.91; p for int

173 the efficacy and safety of ticagrelor versus prasugrel in a head-to-head comparison in patients with

174 Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST

175 The clinical impact of treatment with prasugrel in patients with ACS who have high platelet re

176 ctive, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT0

177 lative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for

178 its and risks of ticagrelor as compared with prasugrel in patients with non-ST-segment elevation acut

179 ive efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment-elevation myocardi

180 ing RPs strongly correlates with response to prasugrel in patients with STEMI treated with PCI.

181 elor maintenance therapy was not superior to prasugrel in preventing coronary microvascular injury in

182 ing compared with the known P2Y12 antagonist prasugrel in rabbit efficacy/bleeding models.

183 duced platelet reactivity in comparison with prasugrel in the acute and chronic phases of treatment,

184 farction randomized to receive ticagrelor or prasugrel in the setting of the ISAR REACT-5 trial (Intr

185 pirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improve

186 Prasugrel increased spontaneous, but not procedural, maj

187 let reactivity compared with oral aspirin on prasugrel-inhibited platelets.

188 alicylate (LA) compared with oral aspirin on prasugrel-inhibited platelets.

189 Twenty-one patients (5.6%) received prasugrel instead of clopidogrel.

190 or or tirofiban were both superior to chewed prasugrel (IPA, 10.5+/-11.0; P<0.001 for both comparison

191 s study sought to determine whether crushing prasugrel is associated with more favorable drug bioavai

192 s study was to determine whether response to prasugrel is associated with the proportion of circulati

193 asugrel LD, and 2, 6, 24, and 72 hours after prasugrel LD in 149 patients with evaluable platelet fun

194 2Y12 Reaction Units (PRU) immediately before prasugrel LD, and 2, 6, 24, and 72 hours after prasugrel

195 In STEMI patients undergoing PPCI, crushed prasugrel leads to faster drug absorption, and consequen

196 Compared with whole tablets, crushed prasugrel led to reduced P2Y12 reaction units by 30 min

197 Adding a prasugrel loading dose (LD) to a clopidogrel LD could be

198 ransferring From Clopidogrel Loading Dose To Prasugrel Loading Dose In Acute Coronary Syndrome Patien

199 ned to either crushed or integral tablets of prasugrel loading dose.

200 pharmacodynamic (PD) response to the reduced prasugrel maintenance dose of 5 mg in very elderly (VE)

201 ss coronary microvascular injury compared to prasugrel maintenance therapy.

202 This study sought to evaluate whether prasugrel may serve as an alternative to clopidogrel in

203 ial heterogeneity of the treatment effect of prasugrel (mean absolute reduction in the ischemia risk

204 Clopidogrel and prasugrel metabolite levels, cytochrome P450 1A2 activit

205 ients receiving ticagrelor (n = 258, 45%) or prasugrel (n = 313, 55%) undergoing PCI were enrolled in

206 neous coronary intervention receiving either prasugrel (n = 95) or ticagrelor (n = 205) loading dose

207 0 mg of prasugrel), or 60-mg loading dose of prasugrel (n=42).

208 maintenance therapy of ticagrelor (n=56) or prasugrel (n=54) after primary percutaneous coronary int

209 ance dose of aspirin and clopidogrel (n=45), prasugrel (n=6), or ticagrelor (n=3).

210 In contrast to prasugrel nonresponders (35 subjects), the prasugrel res

211 6 574) and 17% (n=9247) of patients received prasugrel on hospital discharge.

212 There was no impact of pre-treatment with prasugrel on the presence of thrombus before PCI or on o

213 te Coronary Syndromes) trial of aspirin plus prasugrel or clopidogrel following ACS.

214 Choice of initial antiplatelet agent (prasugrel or clopidogrel).

215 Infarction 38), which randomized patients to prasugrel or clopidogrel, 12,844 patients with ACS recei

216 undergo revascularization were randomized to prasugrel or clopidogrel.

217 nemia were randomly assigned to receive oral prasugrel or placebo for 9 to 24 months.

218 nts that occurred while patients were taking prasugrel or placebo, and of discontinuations due to pra

219 l or placebo, and of discontinuations due to prasugrel or placebo, did not differ significantly betwe

220 The use of prasugrel or ticagrelor eliminated bleeding differences

221 tor included clopidogrel in 2649 (16.5%) and prasugrel or ticagrelor in 13 408 (83.5%) patients.

222 recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina

223 rvention.The primary outcome was the rate of prasugrel or ticagrelor prescribing in each arm.

224 The use of prasugrel or ticagrelor was significantly higher in the

225 ous coronary intervention were randomized to prasugrel or ticagrelor with an intended treatment durat

226 of newer oral P2Y(12) inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhib

227 randomly assigned across 14 sites to either prasugrel or ticagrelor, which was initiated before perc

228 d the progressive switch from clopidogrel to prasugrel or ticagrelor.

229 Patients with HPR (>46 U) were switched to prasugrel or treated with high-dose clopidogrel, and tho

230 lus and 2-hour infusion followed by 60 mg of prasugrel), or 60-mg loading dose of prasugrel (n=42).

231 t with a potent P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glyc

232 e trilemma of selecting between clopidogrel, prasugrel, or ticagrelor.

233 lacebo and 139 +/- 32 for patients receiving prasugrel, P = .10), platelet-leukocyte aggregates, or i

234 The endpoint occurred in 6.6% of prasugrel patients and in 5.7% of ticagrelor patients (h

235 12 months of thienopyridine (clopidogrel or prasugrel) plus aspirin, eligible patients remained on a

236 ter treatment adjustments in those with HPR, prasugrel provided significantly more potent platelet in

237 CI, patients who received pre-treatment with prasugrel received an additional 30-mg dose of prasugrel

238 In comparison with clopidogrel, prasugrel reduced myocardial infarction (HR, 0.81 [95% C

239 to receive a standard dose of ticagrelor or prasugrel (reduced dose in the elderly or low-weight gro

240 ents with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a le

241 o prasugrel nonresponders (35 subjects), the prasugrel responders had smaller reaction-induced increa

242 r (100 mg) than the standard loading dose of prasugrel results in greater and more consistent platele

243 reactivity index, and PK by plasma levels of prasugrel's active metabolite.

244 In patients with STEMI, prasugrel showed to be noninferior as compared with tica

245 Prasugrel significantly reduced the incidence of MI or c

246 standard treatment with either ticagrelor or prasugrel (standard-treatment group) for 12 months.

247 cally meaningful interaction of aspirin with prasugrel, suggesting that previous observations with po

248 Prehospital administration of crushed prasugrel tablets does not improve TIMI 3 flow in the in

249 significantly lower among those who received prasugrel than among those who received placebo.

250 significantly lower among those who received prasugrel than among those who received ticagrelor, and

251 ion were randomly assigned to clopidogrel or prasugrel.The primary endpoint was cardiovascular death,

252 threatening bleeding with pre-treatment with prasugrel; the same trends persisted in patients who had

253 grelor therapy, switching from ticagrelor to prasugrel therapy was associated with an increase in pla

254 and pharmacodynamics (PD) of clopidogrel and prasugrel therapy.

255 Among patients who had angiography who took prasugrel there were fewer cardiovascular deaths, myocar

256 clopidogrel, 2125 (5.2%) were discharged on prasugrel; this frequency steadily increased from 0% to

257 comes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) stud

258 comes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38), whi

259 ot better in patients with ticagrelor versus prasugrel (ticagrelor, -13.9 U; prasugrel, -13.5 U; P=0.

260 ifferent oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemp

261 comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary

262 rategies were examined: generic clopidogrel, prasugrel, ticagrelor, and genotyping for polymorphisms

263 trials of potent P2Y12 inhibitors, including prasugrel, ticagrelor, and intravenous cangrelor.

264 ensitivity troponin assays, a preference for prasugrel/ticagrelor and fondaparinux for anticoagulatio

265 dial approach was used in 21.3% of patients, prasugrel/ticagrelor was used in 18.1% of patients, and

266 f ADP receptor inhibitor (clopidogrel versus prasugrel/ticagrelor).

267 -of-function allele carriers were started on prasugrel/ticagrelor, while 47% were started on clopidog

268 at discharge were associated with switching prasugrel to clopidogrel.

269 h TAXUS Liberte paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT)

270 esistance was not superior in ticagrelor- or prasugrel-treated patients (ticagrelor, 21 [interquartil

271 ia-related hospitalizations was noted in the prasugrel-treated patients when analyses were performed

272 ly lower in clopidogrel-treated smokers than prasugrel-treated smokers (least squares mean treatment

273 MI was significantly reduced with prolonged prasugrel treatment (1.9% versus 7.1%; HR, 0.255; P<0.00

274 e) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio [HR]

275 ater antiplatelet effects were present after prasugrel treatment regardless of smoking status (p < 0.

276 d with increased platelet reactivity despite prasugrel treatment.

277 cked, and stratified by use of ticagrelor or prasugrel, type of acute coronary syndrome (ST-segment e

278 se findings support deferring treatment with prasugrel until a decision is made about revascularizati

279 Using instrumental variable methods, prasugrel use was associated with a lower rate of the ma

280 A steady, linear increase in prasugrel use was seen during the study period, with dis

281 The efficacy and safety of a reduced dose of prasugrel versus a standard dose of ticagrelor in elderl

282 significantly reduced by both ticagrelor and prasugrel versus clopidogrel (28%-50% range of reduction

283 event-driven costs with use of ticagrelor or prasugrel versus clopidogrel according to varying levels

284 ly greater at 24 and 48 h after switching to prasugrel versus continued therapy with ticagrelor, alth

285 no significant differences in mortality (HR prasugrel versus ticagrelor, 1.10 [95% CI, 0.94-1.29] an

286 Those discharged on prasugrel (versus clopidogrel) had a slightly higher lik

287 Switching clopidogrel to prasugrel was associated with high-risk angiographic cha

288 Withdrawal of prasugrel was followed by an increase in MI after both 1

289 Pre-treatment with prasugrel was not associated with decreases in any ische

290 Genotyping with prasugrel was superior to prasugrel alone, with an ICER

291 In patients with NSTE-ACS, we found that prasugrel was superior to ticagrelor in reducing the com

292 Genotyping with prasugrel was the preferred therapy among patients who c

293 HPR with high-dose clopidogrel, but not with prasugrel, was an independent predictor of the composite

294 changes in adverse events with ticagrelor or prasugrel were calculated by applying treatment effects

295 primary percutaneous intervention (PCI) and prasugrel were tested for platelet reactivity using puri

296 lity-weighted event rates favored ticagrelor/prasugrel, whereas clopidogrel reduced utility-weighted

297 e sought to determine whether treatment with prasugrel, which inhibits platelet activation by blockin

298 nts yielded greater IPA compared with chewed prasugrel, which led to higher active metabolite concent

299 e directly compared genotyping strategies or prasugrel with ticagrelor.

300 rvention, who received either clopidogrel or prasugrel within 24 hours of admission at 361 US hospita